Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure

Journal of Cardiac Failure

Volumn 7, Issue 2, 2001, Pages 176-182

  Packer, M ^a  

^a The New York Presbyterian Hospital   (United States)

Author keywords

Clinical trials; Devices; Drugs; End points

Indexed keywords

CYTOKINE ANTIBODY; ENDOTHELIN RECEPTOR ANTAGONIST; VASOPRESSIN ANTAGONIST;

ARTIFICIAL HEART PACEMAKER; DEVICE; DRUG EFFICACY; HEART FAILURE; HUMAN; MEDICAL RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM;

EID: 0034989568     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2001.25652     Document Type: Article

References (12)

1. Role of surrogate endpoints in the evaluation of drugs for heart failure
2. Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure
3. How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men
4. The placebo effect in heart failure
5. Consensus recommendations for the management of chronic heart failure
6. Spectrum and outcome of congestive heart failure in a hospitalized population
7. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure
8. Absence of effect on exercise capacity of 12-week treatment with ramipril in patients with moderate congestive heart failure
9. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
10. Metaanalysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure
11. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure
12. The effects of oral ibopamine in patients with mild heart failure - A double blind placebo controlled comparison to furosemide